amiodarone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiarrhythmics 176 1951-25-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • amiodarone
  • amidorone
  • sedacoron
  • amiodarone hydrochloride
  • amiodarone HCl
An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
  • Molecular weight: 645.32
  • Formula: C25H29I2NO3
  • CLOGP: 8.95
  • LIPINSKI: 2
  • HAC: 4
  • HDO: 0
  • TPSA: 42.68
  • ALOGS: -5.13
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O
0.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.70 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 41.37 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 820 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 24, 1985 FDA WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Torsade de pointes 949.30 45.02 187 3184 2059 2352655
Electrocardiogram QT prolonged 860.28 45.02 216 3155 7598 2347116
Hyperthyroidism 851.97 45.02 169 3202 1928 2352786
Bradycardia 774.59 45.02 209 3162 9772 2344942
Drug interaction 762.26 45.02 264 3107 28899 2325815
Atrial fibrillation 620.97 45.02 189 3182 13579 2341135
Pulmonary toxicity 608.47 45.02 107 3264 582 2354132
Ventricular tachycardia 568.29 45.02 129 3242 2882 2351832
Interstitial lung disease 459.65 45.02 132 3239 7680 2347034
Dyspnoea 434.85 45.02 238 3133 78495 2276219
Hypothyroidism 390.16 45.02 103 3268 4354 2350360
Toxicity to various agents 386.60 45.02 167 3204 32587 2322127
Syncope 355.99 45.02 131 3240 16744 2337970
Ventricular fibrillation 328.29 45.02 78 3293 2123 2352591
Cardiac arrest 315.07 45.02 116 3255 14814 2339900
Hypotension 310.59 45.02 143 3228 32293 2322421
International normalised ratio increased 284.41 45.02 90 3281 7246 2347468
Myxoedema coma 282.10 45.02 40 3331 25 2354689
Hypokalaemia 278.23 45.02 97 3274 10557 2344157
Cardiogenic shock 273.43 45.02 69 3302 2422 2352292
Acute kidney injury 250.30 45.02 118 3253 28004 2326710
Pulmonary fibrosis 235.47 45.02 62 3309 2578 2352136
Cardiac failure 204.35 45.02 80 3291 12014 2342700
Cardio-respiratory arrest 188.64 45.02 70 3301 9076 2345638
Mitral valve incompetence 185.49 45.02 51 3320 2499 2352215
Asthenia 173.13 45.02 110 3261 46816 2307898
Hypomagnesaemia 171.42 45.02 48 3323 2516 2352198
Long QT syndrome 166.06 45.02 35 3336 538 2354176
Hyponatraemia 163.10 45.02 70 3301 13255 2341459
Drug hypersensitivity 161.29 45.02 105 3266 46538 2308176
Respiratory failure 158.81 45.02 69 3302 13459 2341255
Tachyarrhythmia 156.37 45.02 34 3337 610 2354104
Ventricular extrasystoles 150.76 45.02 41 3330 1925 2352789
Hypoxia 148.19 45.02 53 3318 6174 2348540
Thyroiditis 143.78 45.02 29 3342 354 2354360
Sinus bradycardia 143.18 45.02 40 3331 2076 2352638
Renal failure 142.38 45.02 69 3302 17280 2337434
Gastrointestinal haemorrhage 141.28 45.02 62 3309 12373 2342341
Lung disorder 140.79 45.02 51 3320 6161 2348553
Lymphatic fistula 139.53 45.02 19 3352 4 2354710
Cough 135.46 45.02 83 3288 33034 2321680
Femoral hernia incarcerated 135.13 45.02 19 3352 10 2354704
Palpitations 133.66 45.02 65 3306 16391 2338323
Oedema peripheral 132.86 45.02 73 3298 23690 2331024
Hyperkalaemia 132.12 45.02 48 3323 5845 2348869
Dizziness 130.66 45.02 101 3270 58564 2296150
Drug ineffective 127.44 45.02 126 3245 101498 2253216
Pancreatic steatosis 122.97 45.02 19 3352 36 2354678
Pneumonitis 117.70 45.02 40 3331 3999 2350715
Inflammatory marker increased 115.58 45.02 26 3345 548 2354166
General physical health deterioration 115.23 45.02 56 3315 14083 2340631
Wound infection pseudomonas 114.49 45.02 19 3352 67 2354647
Liver function test abnormal 113.97 45.02 46 3325 7444 2347270
Multiple organ dysfunction syndrome 113.08 45.02 46 3325 7595 2347119
Pleural effusion 112.83 45.02 52 3319 11616 2343098
Infusion site phlebitis 110.45 45.02 17 3354 31 2354683
Pulmonary hypertension 108.44 45.02 40 3331 5078 2349636
Acute respiratory distress syndrome 105.40 45.02 35 3336 3257 2351457
Drug-induced liver injury 105.29 45.02 36 3335 3663 2351051
Arterial haemorrhage 104.78 45.02 20 3351 179 2354535
Fatigue 103.91 45.02 104 3267 84769 2269945
Vomiting 103.17 45.02 96 3275 71506 2283208
Condition aggravated 103.01 45.02 69 3302 31910 2322804
Tremor 100.57 45.02 58 3313 20603 2334111
Ventricular arrhythmia 97.77 45.02 23 3348 594 2354120
Anaemia 97.74 45.02 69 3302 34723 2319991
Tricuspid valve incompetence 97.09 45.02 28 3343 1628 2353086
Hepatotoxicity 95.66 45.02 33 3338 3448 2351266
Haemarthrosis 95.11 45.02 21 3350 405 2354309
Aortic valve stenosis 93.98 45.02 20 3351 322 2354392
Seroma 92.51 45.02 19 3352 255 2354459
Bundle branch block left 91.91 45.02 24 3347 960 2353754
Diverticulum intestinal 90.36 45.02 22 3349 660 2354054
Anuria 90.07 45.02 27 3344 1797 2352917
Brugada syndrome 88.60 45.02 16 3355 102 2354612
Aortic arteriosclerosis 86.93 45.02 21 3350 609 2354105
Left ventricular dysfunction 86.42 45.02 24 3347 1216 2353498
Wheezing 86.17 45.02 36 3335 6348 2348366
Hepatic cyst 85.87 45.02 21 3350 642 2354072
Decreased appetite 85.06 45.02 59 3312 28832 2325882
Nausea 84.90 45.02 107 3264 112082 2242632
Toxic skin eruption 84.37 45.02 27 3344 2233 2352481
Keratopathy 82.88 45.02 15 3356 97 2354617
Pneumonia 82.50 45.02 72 3299 49224 2305490
Photosensitivity reaction 82.48 45.02 27 3344 2400 2352314
Tachycardia 82.31 45.02 47 3324 16362 2338352
Atrial flutter 77.72 45.02 22 3349 1195 2353519
Extrasystoles 76.91 45.02 21 3350 998 2353716
Groin pain 75.47 45.02 22 3349 1328 2353386
Wound dehiscence 74.69 45.02 19 3352 684 2354030
Aplastic anaemia 74.65 45.02 20 3351 884 2353830
Atrioventricular block complete 74.46 45.02 22 3349 1392 2353322
Faecaloma 74.41 45.02 20 3351 895 2353819
Fall 73.22 45.02 66 3305 47033 2307681
Extravasation 73.02 45.02 19 3352 749 2353965
Dyspnoea exertional 72.99 45.02 31 3340 5689 2349025
Transaminases increased 72.60 45.02 29 3342 4558 2350156
Alveolitis 72.55 45.02 17 3354 431 2354283
Arrhythmia 71.43 45.02 31 3340 5997 2348717
Overdose 71.42 45.02 46 3325 19861 2334853
Corneal deposits 70.20 45.02 13 3358 97 2354617
Neuromyopathy 70.07 45.02 14 3357 162 2354552
Sinus node dysfunction 70.02 45.02 18 3353 676 2354038
Hepatic failure 69.85 45.02 30 3341 5659 2349055
Eructation 69.68 45.02 20 3351 1142 2353572
Blood thyroid stimulating hormone increased 68.11 45.02 19 3352 978 2353736
Escherichia infection 66.75 45.02 20 3351 1328 2353386
Electrocardiogram QRS complex prolonged 66.22 45.02 19 3352 1083 2353631
Rectal haemorrhage 65.76 45.02 29 3342 5827 2348887
Myelodysplastic syndrome 65.43 45.02 23 3348 2537 2352177
Joint dislocation 65.23 45.02 20 3351 1436 2353278
Rhabdomyolysis 65.12 45.02 30 3341 6674 2348040
Postoperative wound infection 64.69 45.02 19 3352 1177 2353537
Haematuria 60.44 45.02 25 3346 4293 2350421
Lung infiltration 60.39 45.02 21 3350 2243 2352471
Atrioventricular block 60.01 45.02 18 3353 1199 2353515
Atrial tachycardia 59.97 45.02 14 3357 349 2354365
Hepatic cirrhosis 59.60 45.02 21 3350 2332 2352382
Cardiovascular disorder 59.58 45.02 21 3350 2334 2352380
Urinary tract infection 58.77 45.02 48 3323 29894 2324820
Labelled drug-drug interaction medication error 58.73 45.02 18 3353 1290 2353424
Alveolar proteinosis 58.50 45.02 11 3360 90 2354624
Cholestasis 57.05 45.02 23 3348 3698 2351016
Gait disturbance 56.99 45.02 42 3329 22503 2332211
Orthopnoea 56.60 45.02 15 3356 635 2354079
Confusional state 56.31 45.02 43 3328 24301 2330413
Osteopenia 55.69 45.02 19 3352 1916 2352798
Diarrhoea 55.68 45.02 75 3296 83489 2271225
Malaise 55.07 45.02 61 3310 55524 2299190
Blood creatinine increased 55.01 45.02 31 3340 10502 2344212
Aspartate aminotransferase increased 54.96 45.02 33 3338 12579 2342135
Lower respiratory tract infection 54.96 45.02 25 3346 5399 2349315
Cardiac failure congestive 54.77 45.02 36 3335 16065 2338649
Hiatus hernia 54.31 45.02 19 3352 2065 2352649
Thrombocytopenia 53.74 45.02 38 3333 19093 2335621
Cerebral haematoma 53.29 45.02 14 3357 573 2354141
Drug level increased 52.50 45.02 20 3351 2767 2351947
Atrioventricular block second degree 51.31 45.02 14 3357 663 2354051
Renal impairment 50.80 45.02 29 3342 10063 2344651
Mixed liver injury 50.77 45.02 12 3359 316 2354398
Lung consolidation 49.84 45.02 13 3358 517 2354197
Coronary artery disease 49.74 45.02 24 3347 5915 2348799
Nodal rhythm 48.95 45.02 12 3359 370 2354344
Ascites 47.94 45.02 23 3348 5597 2349117
Hyperglobulinaemia 47.88 45.02 7 3364 7 2354707
Oedema 47.85 45.02 28 3343 10175 2344539
Organising pneumonia 47.82 45.02 14 3357 857 2353857
Haemodynamic instability 47.78 45.02 15 3356 1164 2353550
Ataxia 47.36 45.02 18 3353 2474 2352240
Urinary retention 47.19 45.02 20 3351 3647 2351067
Oxygen saturation decreased 46.99 45.02 25 3346 7561 2347153
Alanine aminotransferase increased 46.80 45.02 31 3340 14001 2340713
Shock haemorrhagic 46.53 45.02 15 3356 1268 2353446
Hyperhidrosis 46.49 45.02 32 3339 15390 2339324
Presyncope 46.48 45.02 20 3351 3783 2350931
Neurotoxicity 46.38 45.02 17 3354 2113 2352601
Foetal exposure during pregnancy 46.34 45.02 22 3349 5230 2349484
Acute hepatic failure 46.34 45.02 18 3353 2624 2352090
Hepatic steatosis 46.31 45.02 19 3352 3194 2351520

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthyroidism 2170.59 39.21 411 4833 1171 1740366
Drug interaction 1239.07 39.21 478 4766 27480 1714057
Pulmonary toxicity 1097.08 39.21 210 5034 629 1740908
Bradycardia 853.38 39.21 283 4961 10251 1731286
Ventricular tachycardia 833.76 39.21 221 5023 3577 1737960
Interstitial lung disease 803.11 39.21 265 4979 9431 1732106
Atrial fibrillation 720.65 39.21 274 4970 14837 1726700
Pulmonary fibrosis 686.30 39.21 174 5070 2330 1739207
Dyspnoea 680.37 39.21 383 4861 51676 1689861
Hypothyroidism 677.55 39.21 173 5071 2387 1739150
Toxicity to various agents 610.68 39.21 295 4949 28846 1712691
Thyroiditis 541.49 39.21 103 5141 291 1741246
Torsade de pointes 478.44 39.21 115 5129 1209 1740328
Electrocardiogram QT prolonged 467.53 39.21 154 5090 5391 1736146
Cardiac failure 400.10 39.21 171 5073 12431 1729106
Drug ineffective 367.07 39.21 282 4962 63519 1678018
International normalised ratio increased 363.73 39.21 142 5102 8157 1733380
Respiratory failure 358.02 39.21 165 5079 14340 1727197
Hypotension 343.84 39.21 203 5041 29451 1712086
Acute kidney injury 313.10 39.21 203 5041 34741 1706796
Syncope 296.70 39.21 144 5100 14025 1727512
Asthenia 277.92 39.21 188 5056 34482 1707055
Ventricular fibrillation 266.26 39.21 85 5159 2671 1738866
Cardiac arrest 266.26 39.21 139 5105 15791 1725746
Pulmonary alveolar haemorrhage 241.55 39.21 65 5179 1100 1740437
Dizziness 239.27 39.21 171 5073 34190 1707347
Acute respiratory distress syndrome 237.40 39.21 83 5161 3468 1738069
Lung disorder 204.35 39.21 82 5162 5037 1736500
Pneumonitis 203.55 39.21 76 5168 3839 1737698
Thyrotoxic crisis 197.76 39.21 36 5208 72 1741465
Myxoedema coma 185.91 39.21 33 5211 53 1741484
Cough 184.78 39.21 117 5127 19080 1722457
Hepatotoxicity 179.23 39.21 65 5179 3019 1738518
Drug-induced liver injury 168.81 39.21 63 5181 3174 1738363
Atrial flutter 159.49 39.21 53 5191 1889 1739648
Organising pneumonia 157.76 39.21 44 5200 854 1740683
Venous pressure jugular increased 154.40 39.21 29 5215 74 1741463
Drug hypersensitivity 152.44 39.21 95 5149 15040 1726497
Condition aggravated 150.76 39.21 107 5137 21043 1720494
Pleural effusion 149.21 39.21 84 5160 11026 1730511
Fatigue 146.99 39.21 153 5091 50628 1690909
Thyroid disorder 146.75 39.21 37 5207 477 1741060
Palpitations 144.49 39.21 70 5174 6744 1734793
Pneumonia 144.24 39.21 145 5099 46037 1695500
Phlebitis 142.84 39.21 39 5205 697 1740840
Renal failure 142.02 39.21 101 5143 19916 1721621
Pulmonary oedema 140.68 39.21 68 5176 6518 1735019
Dyspnoea exertional 139.95 39.21 59 5185 4102 1737435
Oedema peripheral 135.24 39.21 89 5155 15461 1726076
Hypoxia 134.75 39.21 64 5180 5899 1735638
Oedema 131.31 39.21 66 5178 6882 1734655
Rhabdomyolysis 128.00 39.21 76 5168 11014 1730523
Atrioventricular block 127.02 39.21 41 5203 1330 1740207
Multiple organ dysfunction syndrome 124.38 39.21 70 5174 9172 1732365
Ventricular arrhythmia 121.10 39.21 34 5210 676 1740861
Liver function test abnormal 115.89 39.21 57 5187 5669 1735868
Sinus bradycardia 113.22 39.21 41 5203 1892 1739645
Pericardial effusion 110.42 39.21 47 5197 3343 1738194
Arrhythmia 107.38 39.21 55 5189 5961 1735576
Cardiac failure congestive 105.78 39.21 76 5168 15194 1726343
Anaemia 103.87 39.21 99 5145 29358 1712179
Left ventricular dysfunction 103.20 39.21 34 5210 1177 1740360
Alanine aminotransferase increased 101.18 39.21 68 5176 12210 1729327
Respiratory distress 100.38 39.21 50 5194 5107 1736430
Haemoptysis 100.03 39.21 49 5195 4827 1736710
Tachycardia 99.44 39.21 68 5176 12560 1728977
Cardiac murmur 98.90 39.21 33 5211 1189 1740348
Blood thyroid stimulating hormone increased 97.26 39.21 28 5216 611 1740926
Infusion site phlebitis 96.65 39.21 17 5227 25 1741512
Hepatic cirrhosis 93.80 39.21 39 5205 2614 1738923
Keratopathy 92.95 39.21 18 5226 57 1741480
Left ventricular failure 90.38 39.21 27 5217 673 1740864
Bundle branch block left 90.13 39.21 28 5216 799 1740738
Neurotoxicity 89.67 39.21 35 5209 1989 1739548
Product use in unapproved indication 89.36 39.21 57 5187 9365 1732172
Heart rate decreased 88.35 39.21 38 5206 2771 1738766
Cardio-respiratory arrest 87.58 39.21 56 5188 9237 1732300
Aspartate aminotransferase increased 87.23 39.21 59 5185 10697 1730840
Myopathy 86.18 39.21 33 5211 1780 1739757
Wheezing 85.97 39.21 42 5202 4111 1737426
Atrioventricular block complete 85.38 39.21 31 5213 1440 1740097
Lung infiltration 84.02 39.21 34 5210 2125 1739412
Fall 83.83 39.21 85 5159 27129 1714408
Tremor 81.07 39.21 61 5183 13070 1728467
Gait disturbance 80.76 39.21 60 5184 12610 1728927
Corneal deposits 80.63 39.21 17 5227 91 1741446
Labelled drug-drug interaction medication error 80.39 39.21 29 5215 1322 1740215
Acute hepatic failure 78.91 39.21 32 5212 2011 1739526
Hepatic enzyme increased 77.94 39.21 46 5198 6575 1734962
Chest pain 77.94 39.21 71 5173 19843 1721694
Long QT syndrome 76.55 39.21 20 5224 299 1741238
Malaise 76.22 39.21 84 5160 29481 1712056
Weight decreased 75.45 39.21 74 5170 22679 1718858
Prothrombin time prolonged 75.24 39.21 29 5215 1592 1739945
Potentiating drug interaction 72.80 39.21 23 5221 694 1740843
Blindness 72.38 39.21 33 5211 2763 1738774
Hyperglobulinaemia 72.35 39.21 12 5232 9 1741528
Blood creatinine increased 71.38 39.21 58 5186 13888 1727649
Muscular weakness 70.88 39.21 51 5193 10198 1731339
Neuropathy peripheral 70.84 39.21 49 5195 9204 1732333
Cholestasis 69.72 39.21 35 5209 3630 1737907
Hepatic failure 69.44 39.21 41 5203 5862 1735675
Dissociation 69.21 39.21 18 5226 264 1741273
Traumatic lung injury 68.11 39.21 18 5226 282 1741255
General physical health deterioration 68.07 39.21 55 5189 13063 1728474
Paraesthesia 67.72 39.21 50 5194 10401 1731136
Supraventricular tachycardia 67.50 39.21 27 5217 1636 1739901
Haematuria 67.37 39.21 44 5200 7516 1734021
Nausea 66.90 39.21 104 5140 51092 1690445
Ventricular extrasystoles 66.88 39.21 28 5216 1908 1739629
Coagulopathy 66.30 39.21 31 5213 2750 1738787
Activated partial thromboplastin time prolonged 66.06 39.21 25 5219 1305 1740232
Epistaxis 65.97 39.21 45 5199 8261 1733276
Acute respiratory failure 64.65 39.21 31 5213 2909 1738628
Optic neuropathy 64.13 39.21 18 5226 357 1741180
Cardiogenic shock 63.63 39.21 29 5215 2425 1739112
Heart rate irregular 63.62 39.21 26 5218 1666 1739871
Crepitations 63.12 39.21 19 5225 486 1741051
Hyponatraemia 62.71 39.21 45 5199 8955 1732582
Rales 62.56 39.21 22 5222 930 1740607
Cardiac failure acute 61.04 39.21 23 5221 1186 1740351
Treatment failure 60.94 39.21 34 5210 4367 1737170
Cornea verticillata 60.58 39.21 10 5234 7 1741530
Orthostatic hypotension 60.11 39.21 31 5213 3400 1738137
Hypothermia 59.43 39.21 25 5219 1723 1739814
Haemorrhage 59.16 39.21 45 5199 9784 1731753
Haemodynamic instability 58.79 39.21 23 5221 1314 1740223
Goitre 58.56 39.21 16 5228 286 1741251
Cardiac failure chronic 58.46 39.21 19 5225 629 1740908
Jaundice 58.25 39.21 37 5207 6025 1735512
Loss of consciousness 58.08 39.21 53 5191 14822 1726715
Ejection fraction decreased 56.54 39.21 26 5218 2219 1739318
Leukocytosis 56.42 39.21 30 5214 3503 1738034
Cardiomegaly 55.58 39.21 26 5218 2308 1739229
Thyroxine free increased 54.40 39.21 11 5233 46 1741491
Hyperhidrosis 53.71 39.21 47 5197 12441 1729096
Hyperkalaemia 53.36 39.21 40 5204 8507 1733030
Blood thyroid stimulating hormone decreased 53.32 39.21 15 5229 300 1741237
Haemoglobin decreased 51.78 39.21 53 5191 17061 1724476
Vomiting 51.59 39.21 79 5165 38236 1703301
Extravasation 51.34 39.21 17 5227 597 1740940
Jugular vein distension 51.29 39.21 12 5232 110 1741427
Drug level increased 51.28 39.21 26 5218 2751 1738786
Blood pressure decreased 50.45 39.21 37 5207 7609 1733928
Respiratory depression 50.33 39.21 24 5220 2223 1739314
Visual impairment 50.10 39.21 34 5210 6184 1735353
Pulseless electrical activity 50.02 39.21 19 5225 1001 1740536
Halo vision 49.76 39.21 11 5233 76 1741461
Atrial tachycardia 49.25 39.21 14 5230 291 1741246
International normalised ratio abnormal 49.17 39.21 18 5226 855 1740682
Feeling abnormal 47.96 39.21 42 5202 11124 1730413
Orthopnoea 47.07 39.21 16 5228 610 1740927
Tachypnoea 46.25 39.21 23 5221 2335 1739202
Hepatitis acute 46.17 39.21 19 5225 1238 1740299
Bundle branch block right 46.06 39.21 19 5225 1246 1740291
Liver disorder 45.84 39.21 31 5213 5605 1735932
Non-alcoholic steatohepatitis 44.80 39.21 11 5233 126 1741411
Thyroxine increased 44.25 39.21 9 5235 39 1741498
Pulmonary haemorrhage 43.80 39.21 20 5224 1679 1739858
Blood alkaline phosphatase increased 43.27 39.21 29 5215 5166 1736371
Cardiac tamponade 43.26 39.21 17 5227 982 1740555
Vision blurred 42.99 39.21 35 5209 8388 1733149
Tachycardia induced cardiomyopathy 42.98 39.21 8 5236 19 1741518
Hypokalaemia 42.40 39.21 31 5213 6343 1735194
Cardioactive drug level increased 42.33 39.21 12 5232 247 1741290
Hepatocellular injury 42.11 39.21 24 5220 3207 1738330
Lymphoid tissue hyperplasia 42.10 39.21 9 5235 52 1741485
Chronic obstructive pulmonary disease 41.99 39.21 30 5214 5923 1735614
Ischaemic hepatitis 41.88 39.21 12 5232 257 1741280
Heart rate increased 41.81 39.21 31 5213 6479 1735058
Diaphragmatic paralysis 41.78 39.21 10 5234 102 1741435
Neuromyopathy 41.57 39.21 11 5233 173 1741364
Mental status changes 41.44 39.21 30 5214 6045 1735492
Oesophageal achalasia 41.26 39.21 9 5235 58 1741479
Melaena 40.81 39.21 28 5216 5182 1736355
Atrioventricular block first degree 40.79 39.21 16 5228 920 1740617
Cerebral haematoma 40.62 39.21 15 5229 730 1740807
Thrombophlebitis 40.56 39.21 14 5230 559 1740978
Presyncope 40.52 39.21 22 5222 2676 1738861
Haematoma 40.19 39.21 25 5219 3920 1737617
Electrocardiogram QRS complex prolonged 40.05 39.21 15 5229 760 1740777
Orchitis 39.64 39.21 12 5232 313 1741224
Basedow's disease 39.24 39.21 11 5233 217 1741320

Pharmacologic Action:

SourceCodeDescription
ATC C01BD01 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
ANTIARRHYTHMICS, CLASS I AND III
Antiarrhythmics, class III
FDA EPC N0000175426 Antiarrhythmic
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000182138 Cytochrome P450 1A2 Inhibitors
FDA MoA N0000185504 Cytochrome P450 2C9 Inhibitors
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA D065688 Cytochrome P-450 CYP2C9 Inhibitors
MeSH PA D065690 Cytochrome P-450 CYP2D6 Inhibitors
MeSH PA D065692 Cytochrome P-450 CYP3A Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D026902 Potassium Channel Blockers
MeSH PA D026941 Sodium Channel Blockers
CHEBI has role CHEBI:35554 cardiovascular drug
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ventricular fibrillation indication 71908006
Prevention of Ventricular Fibrillation indication
Life-Threatening Ventricular Tachycardia indication
Atrial fibrillation off-label use 49436004 DOID:0060224
Cardioversion of Atrial Fibrillation off-label use
Prevention of Post Cardio-Thoracic Surgery Atrial Fibrillation off-label use
Complete atrioventricular block contraindication 27885002
Torsades de pointes contraindication 31722008
Hyperthyroidism contraindication 34486009 DOID:7998
Extrinsic allergic alveolitis contraindication 37471005 DOID:841
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Refractive keratoplasty by laser surgery contraindication 58076004
Sinus node dysfunction contraindication 60423000
Interstitial pneumonia contraindication 64667001
Optic neuritis contraindication 66760008 DOID:1210
Corneal deposit contraindication 74460005 DOID:11547
Disorder of optic nerve contraindication 77157004 DOID:1891
Pulmonary hemorrhage contraindication 78144005
Cardiogenic shock contraindication 89138009
Thyrotoxicosis contraindication 90739004 DOID:7997
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Second degree atrioventricular block contraindication 195042002
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Pregnancy, function contraindication 289908002
Peripheral nerve disease contraindication 302226006
Eosinophilic asthma contraindication 367542003 DOID:9498
Surgical procedure contraindication 387713003
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Congenital long QT syndrome contraindication 442917000
Syncope due to Bradycardia contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium voltage-gated channel subfamily H member 2 Ion channel BLOCKER IC50 5 WOMBAT-PK CHEMBL
Mu-type opioid receptor GPCR Ki 5.11 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.34 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.18 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 5.91 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.65 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.99 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.23 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.67 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.04 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.23 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.39 DRUG MATRIX
Histamine H2 receptor GPCR Ki 4.98 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.20 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.74 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.17 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.30 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 5.97 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 4.50 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.70 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.00 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 5.21 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.18 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 5.55 DRUG MATRIX
Endothelin-1 receptor GPCR Ki 4.79 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 6.09 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.04 DRUG MATRIX
C-C chemokine receptor type 2 GPCR Ki 5.37 DRUG MATRIX
Substance-K receptor GPCR Ki 5.19 DRUG MATRIX
B2 bradykinin receptor GPCR Ki 5.11 DRUG MATRIX
Melanocortin receptor 4 GPCR Ki 4.88 DRUG MATRIX
Melanocortin receptor 5 GPCR Ki 5.05 DRUG MATRIX
Melanocortin receptor 3 GPCR Ki 4.97 DRUG MATRIX
C-C chemokine receptor type 4 GPCR Ki 4.94 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR IC50 6.30 WOMBAT-PK
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 7.10 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7 WOMBAT-PK
Thyroid hormone receptor beta Nuclear hormone receptor IC50 6.22 WOMBAT-PK
Thyroid hormone receptor alpha Nuclear hormone receptor IC50 5.64 WOMBAT-PK
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 7.60 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Ki 6.22 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 7 Ion channel IC50 6 WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 5.30 WOMBAT-PK
Beta-1 adrenergic receptor GPCR IC50 4.70 WOMBAT-PK
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 5.35 WOMBAT-PK
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel Ki 5.28 WOMBAT-PK
Cytochrome P450 2C9 Enzyme EC50 7.40 WOMBAT-PK
THAP domain-containing protein 1 Unclassified IC50 6.19 WOMBAT-PK
Squalene monooxygenase Enzyme IC50 4.92 CHEMBL
Squalene synthase Enzyme IC50 5.10 CHEMBL
Androgen receptor Transcription factor Ki 4.55 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 4.41 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor IC50 6.93 DRUG MATRIX
Cruzipain Enzyme IC50 5.40 CHEMBL
Lethal factor Enzyme IC50 5.46 CHEMBL
C-8 sterol isomerase Enzyme Ki 7.21 CHEMBL
Sodium channel protein type 5 subunit alpha Unclassified BLOCKER IC50 5.70 IUPHAR

External reference:

IDSource
D000638 MESH_DESCRIPTOR_UI
4019606 VUID
N0000147701 NUI
C0002598 UMLSCUI
D00636 KEGG_DRUG
69236009 SNOMEDCT_US
4019606 VANDF
703 RXNORM
372821002 SNOMEDCT_US
d00002 MMSL
004484 NDDF
976728SY6Z UNII
19774-82-4 SECONDARY_CAS_RN
CHEMBL633 ChEMBL_ID
DB01118 DRUGBANK_ID
CHEMBL1083993 ChEMBL_ID
2012 INN_ID
CHEBI:2663 CHEBI
2566 IUPHAR_LIGAND_ID
2157 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9875 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 16 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0144 TABLET 200 mg ORAL ANDA 17 sections
Pacerone HUMAN PRESCRIPTION DRUG LABEL 1 0245-0144 TABLET 100 mg ORAL ANDA 18 sections
Pacerone HUMAN PRESCRIPTION DRUG LABEL 1 0245-0145 TABLET 400 mg ORAL ANDA 17 sections
Pacerone HUMAN PRESCRIPTION DRUG LABEL 1 0245-0147 TABLET 200 mg ORAL ANDA 18 sections
Amiodarone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8213 TABLET 200 mg ORAL ANDA 13 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8258 TABLET 200 mg ORAL ANDA 12 sections
Amiodarone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6556 TABLET 200 mg ORAL ANDA 18 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6993 TABLET 200 mg ORAL ANDA 18 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-843 TABLET 100 mg ORAL ANDA 18 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-844 TABLET 200 mg ORAL ANDA 18 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-845 TABLET 400 mg ORAL ANDA 18 sections
Amiodarone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-796 TABLET 200 mg ORAL ANDA 13 sections
Amiodarone HCl HUMAN PRESCRIPTION DRUG LABEL 1 42494-307 TABLET 100 mg ORAL ANDA 17 sections
Amiodarone HCl HUMAN PRESCRIPTION DRUG LABEL 1 42494-308 TABLET 200 mg ORAL ANDA 17 sections
Amiodarone HCl HUMAN PRESCRIPTION DRUG LABEL 1 42494-309 TABLET 400 mg ORAL ANDA 17 sections
Nexterone HUMAN PRESCRIPTION DRUG LABEL 1 43066-150 INJECTION, SOLUTION 1.50 mg INTRAVENOUS NDA 17 sections
Nexterone HUMAN PRESCRIPTION DRUG LABEL 1 43066-360 INJECTION, SOLUTION 1.80 mg INTRAVENOUS NDA 17 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-3015 TABLET 200 mg ORAL ANDA 12 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-3496 TABLET 200 mg ORAL ANDA 18 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-097 TABLET 100 mg ORAL ANDA 18 sections
AMIODARONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1205 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 17 sections
AMIODARONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1358 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 17 sections
AMIODARONE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1363 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 12 sections
NEXTERONE (AMIODARONE HCI) HUMAN PRESCRIPTION DRUG LABEL 1 51662-1480 INJECTION, SOLUTION 1.50 mg INTRAVENOUS NDA 17 sections
NEXTERONE (AMIODARONE HCI) HUMAN PRESCRIPTION DRUG LABEL 1 51662-1481 INJECTION, SOLUTION 1.80 mg INTRAVENOUS NDA 17 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51672-4025 TABLET 200 mg ORAL ANDA 18 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51672-4055 TABLET 100 mg ORAL ANDA 18 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51672-4056 TABLET 300 mg ORAL ANDA 18 sections
Amiodarone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51672-4057 TABLET 400 mg ORAL ANDA 18 sections